Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
FABP3 Monoclonal Antibody (OTI11B4), TrueMAB™, OriGene

Mouse Monoclonal Antibody
Supplier: OriGene CF814162


Description
FABP3 Monoclonal antibody specifically detects FABP3 in Human samples. It is validated for ELISASpecifications
FABP3 | |
Monoclonal | |
See Label | |
PBS with 8% trehalose and no preservative; pH 7.3 | |
P07196 | |
Mouse | |
Protein A/G | |
RUO | |
4747 | |
-20° C, Avoid Freeze/Thaw Cycles | |
IgG1 |
ELISA | |
OTI11B4 | |
Unconjugated | |
NEFL | |
422 protein; Cardiac Fatty Acid Binding Protein; FABP 3; FABP11; Fabp3; Fabph1; Fabph-1; Fabph4; Fabph-4; fatty acid binding protein 11; Fatty acid binding protein 11 (FABP11); fatty acid binding protein 3; Fatty acid binding protein 3 heart; fatty acid binding protein 3, muscle and heart; Fatty acid binding protein heart; fatty acid binding protein heart 1; fatty acid binding protein heart 4; fatty acid-binding protein 3; Fatty acid-binding protein, heart; heart FABP; heart fatty acid binding protein; Heart type fatty acid binding protein; heart-type fatty acid-binding protein; H-FABP; M FABP; Mammary derived growth inhibitor; Mammary-derived growth inhibitor; MDGI; M-FABP; muscle and heart (mammary derived growth inhibitor); Muscle fatty acid binding protein; Muscle fatty acid-binding protein; Muscle O-FABP; Mylein protein P2 homolog / adopocyte; O-FABP | |
Human recombinant protein fragment corresponding to amino acids 90-400aa of human NEFL (NP_006149) produced in E.coli. | |
100 μg | |
Primary | |
Human | |
Lyophilized |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction